Buffalo, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE INC, founded in 1956, is a mid-sized nonprofit in the Medical Research sector that reported $11.0M in total revenue in fiscal year 2023. Revenue surged 27% from the prior year, signaling strong growth momentum. Expenses of $10.5M left a modest 5% surplus.
Guided by its motto, CURE-OSITY, the Hauptman-Woodward Medical Research Institute (HWI) creates novel strategies and technologies to promote the understanding, prevention, and treatment of many human diseases. HWI scientists conduct basic, fundamental research that will provide for effective therapeutic approaches far into the future. Often our research includes identifying proteins involved in disease which allows treatments to be more effective by targeting those proteins. Examples of current projects include breast cancer, prostate cancer, multiple myeloma, studying the effect of gravity on cells, and biological cell structure determination for nearly all disease through the use of hard X-ray free electron lasers (XFELs) and high-throughput crystallization.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $11,025,702 | $8,691,259 | +0.3% |
| Expenses | $10,453,501 | $9,386,732 | +0.1% |
| Net Income | $572,201 | $-695,473 | -1.8% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Edward Snell | Chief Scientific Officer | 37.5 |
Officer
|
$155,919 | $42,417 | $255,344 |
| Lisa Keefe | VP | 37.5 |
Officer
|
$225,718 | $14,022 | $239,740 |
| Anne Kent | Chief Financial Officer | 37.5 |
Officer
|
$152,939 | $27,072 | $180,011 |
| Devrim Acehan | Cryo-EM Director | 37.5 |
Highest
|
$138,942 | $28,409 | $167,351 |
| Daniel Gewirth | Principal Research Scientist | 37.5 |
Highest
|
$134,964 | $23,158 | $158,122 |
| John Muir | Software Developer | 37.5 |
Highest
|
$122,732 | $30,982 | $153,714 |
| Blanca Carbajal | Business Development Director | 37.5 |
Highest
|
$136,678 | $2,776 | $139,454 |
| Aviv Paz | Principal Investigator | 37.5 |
Highest
|
$102,505 | $29,194 | $131,699 |
| Sarah Bowman | Board Member/Associate Investigator | 37.5 |
Director
|
$99,753 | $23,412 | $123,165 |
| Christopher Greene | Interim CEO | 1 |
Officer
Director
|
$120,000 | $0 | $120,000 |
| Christina Arthurs | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| LaVonne Ansari | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Tricia Barrett | Board Member/Vice Chairperson of the Board | 0.2 |
Officer
Director
|
$0 | $0 | $0 |
| Steve Bell | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Jill Bond | Board Member/Secretary | 0.2 |
Officer
Director
|
$0 | $0 | $0 |
| EJ Burke | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| William Constantine | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Artem Evdokimov | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Frank Ewing | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Venu Govindaraju | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Andrei Gudkov | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| William Harries | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Michele Heffernan | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Dan Magnuszewski | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Brenda McDuffie | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Sean Moskal | Chairman of Finance Committee | 0.2 |
Officer
Director
|
$0 | $0 | $0 |
| Philip Nobel | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Jeffrey Renzoni | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Nena Rich | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Sam Russo | Board Member/Chairperson of the Board | 0.2 |
Officer
Director
|
$0 | $0 | $0 |
| Franca Trincia | Board Member | 0.2 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $11,025,702 | $10,453,501 | $27,556,503 | $572,201 |
| 2023 | $8,691,259 | $9,386,732 | $26,875,141 | $-695,473 |
| 2022 | $6,895,666 | $7,228,048 | $23,417,551 | $-332,382 |
| 2021 | $9,359,091 | $6,944,091 | $26,101,769 | $2,415,000 |
| 2020 | $6,939,060 | $7,407,374 | $22,935,072 | $-468,314 |
| 2019 | $5,204,564 | $7,227,288 | $22,455,303 | $-2,022,724 |
| 2018 | $8,037,897 | $7,462,126 | $22,430,958 | $575,771 |
Compare HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE INC with other nonprofits in New York and across the country.